
Merck Announces Positive Data From Trials For Cholesterol Drug, But Retail Reaction Is Sluggish
Merck (MRK) on Monday announced positive results from the first two of three late-stage clinical trials evaluating the safety and efficacy of its oral cholesterol drug, sending shares of the company trading marginally higher in the morning. Enlicitide …